| Sanofi S.A.. (11/9/21). "Press Release: Sanofi Completes Acquisition of Kadmon". Paris. |
2021-11-09 |
| Sanofi S.A.. (11/9/17). "Press Release: Sanofi, Principia Agree to Develop Multiple Sclerosis Drug Candidate". Paris & South San Francisco, CA. |
2017-11-09 |
| Sanofi S.A.. (11/18/21). "Press Release: Sanofi Invests $180 Million Equity in Owkin’s Artificial Intelligence and Federated Learning to Advance Oncology Pipeline". Paris. |
2021-11-18 |
| Sanofi S.A.. (11/1/18). "Press Release: Sanofi and Denali Therapeutics to Develop Treatments for Neurological and Inflammatory Diseases". Paris. |
2018-11-01 |
| Sanofi S.A.. (10/31/18). "Press Release: Sanofi Q3 2018 Performance Confirms Return to Growth". Paris. |
2018-10-31 |
| Sanofi S.A.. (10/3/23). "Press Release: Sanofi Announces Agreement for Potential First-in-Class Vaccine against Extraintestinal Pathogenic E. coli". Paris. |
2023-10-03 |
| Sanofi S.A.. (10/16/18). "Press Release: Dupixent (dupilumab) Showed Positive Topline Results in Two Phase 3 trials of Patients with Chronic Rhinosinusitis with Nasal Polyps". Paris & Tarrytown, NY. |
2018-10-16 |
| Sanofi S.A.. (10/16/17). "Press Release: Sanofi and Regeneron Announce Positive Phase 2 Study Results for Dupilumab in Patients With Active Moderate-to-Severe Eosinophilic Esophagitis". Paris & Tarrytown, NY. |
2017-10-16 |
| Sanofi S.A.. (10/12/17). "Press Release: Sanofi Invests €170 Million in New Vaccine Production Facility in France". Paris. |
2017-10-12 |
| Sanofi S.A.. (10/1/18). "Press Release: Sanofi Completes Divestiture of Zentiva to Advent". Paris. |
2018-10-01 |
| Sanofi S.A.. (1/8/18). "Press Release: Sanofi and Regeneron to Accelerate and Expand Investment for Cemiplimab and Dupilumab Development Programs". Paris & Tarrytown, NY. |
2018-01-08 |
| Sanofi S.A.. (1/7/19). "Press Release: Sanofi and Regeneron Restructure Immuno-Oncology Collaboration for Discovery and Development Programs". Paris & Tarrytown, NY. |
2019-01-07 |
| Sanofi S.A.. (1/5/17). "Press Release: Sanofi and Regeneron to Appeal U.S. District Court Rulings in Ongoing Patent Litigation Regarding Praluent (alirocumab) Injection". Paris & Tarrytown, NY. |
2017-01-05 |
| Sanofi S.A.. (1/4/17). "Press Release: Sanofi Announces Soliqua 100/33 Now Available in the U.S.". Paris. |
2017-01-04 |
| Sanofi S.A.. (1/31/18). "Press Release: Sanofi, DNDi Seek European Medicines Agency Review for Sleeping Sickness Treatment". Paris & Geneva. |
2018-01-31 |
| Sanofi S.A.. (1/30/19). "Press Release: Fexinidazole, the First All-oral Treatment for Sleeping Sickness, Approved in Democratic Republic of Congo". Paris & Geneva. |
2019-01-30 |
| Sanofi S.A.. (1/30/17). "Press Release: Sanofi Appoints Kathleen Tregoning to Executive Committee and Executive Vice President, External Affairs". Paris. |
2017-01-30 |
| Sanofi S.A.. (1/29/18). "Press Release: Sanofi to Acquire Ablynx for €3.9 Billion". Paris & Ghent. |
2018-01-29 |
| Sanofi S.A.. (1/22/18). "Press Release: Sanofi to Acquire Bioverativ for $11.6 Billion". Paris & Waltham, MA. |
2018-01-22 |
| Sanofi S.A.. (1/2/17). "Press Release: Sanofi and Boehringer Ingelheim Confirm Closing of Business Swap on January 1st 2017". Paris & Ingelheim. |
2017-01-02 |
| Sanofi S.A.. (1/19/18). "Press Release: Sanofi Appoints Dominique Carouge Executive Vice President Head of Business Transformation and Member of the Executive Committee". Paris. |
2018-01-19 |
| Sanofi S.A.. (1/18/17). "Press Release: Suliqua Approved in the European Union for the Treatment of Adults with Type 2 Diabetes". Paris. |
2017-01-18 |
| Sanofi S.A.. (1/17/19). "Press Release: FDA Advisory Committee Votes on Zynquista (sotagliflozin) as Treatment for Adults with Type 1 Diabetes". Paris & The Woodlands, TX. |
2019-01-17 |
| Sanofi S.A.. (1/11/23). "Press Release: Sanofi Ventures Announces Multi-year Capital Commitment from Sanofi, Increasing Evergreen Fund to $750M". Paris. |
2023-01-11 |
| Sanofi S.A.. (1/11/21). "Press Release: Sanofi to Acquire Kymab, Adding KY1005 to Its Pipeline, a Human Monoclonal Antibody Targeting Key Immune System Regulator OX40L". Paris & Cambridge. |
2021-01-11 |
| Roche. (9/11/17). "Press Release: Onxeo Announces Top-line Results from ReLive Phase III Study of Livatag in Advanced Hepatocellular Carcinoma". Paris. |
2017-09-11 |
| Robocath SAS. (5/18/17). "Press Release: Robocath Raises €4.7 million ($5.2M) to Market Its First Medical Robotic Platform, R-one, in 2018". Rouen. |
2017-05-18 |
| Robocath SAS. (4/29/20). "Press Release: Robocath Secures €40 Million Series C Financing Round to Deploy Its Operations Development Plan". Rouen. |
2020-04-29 |
| Robocath SAS. (12/6/17). "Press Release: Robocath Raises a Total of €6.4 million ($7.6M) in 2017". |
2017-12-06 |
| Robocath SAS. (11/2/20). "Press Release: Robocath Finalizes Creation of the Joint Venture with MicroPort through Its Medical Robotic Subsidiary MedBot". Rouen. |
2020-11-02 |
| Ribonexus. (4/12/22). "Press Release: Ribonexus Receives €2M in Deep Tech Financing from Bpifrance". Villejuif. |
2022-04-12 |
| Ribonexus. (11/18/21). "Press Release: Aglaia Therapeutics Becomes Ribonexus and Signs Exclusive License Agreement with Pierre Fabre on Small Molecules Targeting eIF4A, an Innovative Target in Oncology". Villejuif & Castres. |
2021-11-18 |
| Recordati Industria Chimica e Farmaceutica S.p.A.. (1/27/17). "Press Release: Recordati Announces Marketing Approval for Cystadrops". Milan. |
2017-01-27 |
| Quinten Health. (9/20/22). "Press Release: Quinten Health Closes Its Financing Round to Advance Disease Modeling Platforms and Virtual Twins in Real-world". Paris. |
2022-09-20 |
| Quantum Genomics S.A.. (7/26/17). "Press Release: Quantum Genomics Raises EUR 8.2 Million in Europe and the U.S.". |
2017-07-26 |
| Quantum Genomics S.A.. (11/12/18). "Press Release: Quantum Genomics Announces Excellent Topline Results from Phase 2b NEW-HOPE Study Evaluating Firibastat for Arterial Hypertension". Paris & New York, NY. |
2018-11-12 |
| PX’Therapeutics S.A.. (2/20/19). "Press Release: 2019 – PX’Therapeutics Develops Its Services Offer". |
2019-02-20 |
| PX’Therapeutics S.A.. (1/17/18). "Press Release: PX’Therapeutics and Advaxis to Collaborate for the Process Development of Lm Based Immunotherapies". Grenoble. |
2018-01-17 |
| Premaitha Health plc. (2/13/17). "Press Release: New Partnership with Major European Diagnostics Group". Manchester. |
2017-02-13 |
| Poxel S.A.. (5/25/20). "Press Release: Poxel Successfully Raises €17.7 Million in a Capital Increase [Not for US, AU, CA or JP]". Lyon. |
2020-05-25 |
| Poxel S.A.. (5/25/20). "Press Release: Poxel Announces Program Update and Preclinical Results on PXL770 for NASH Combinations and Other Metabolic Diseases". Lyon. |
2020-05-25 |
| Poxel S.A.. (4/25/17). "Press Release: Poxel Announces Appointment of Anne Renevot as Chief Financial Officer". Lyon. |
2017-04-25 |
| Poxel S.A.. (11/5/19). "Press Release: Poxel Obtains Additional Funding to Advance Pipeline Programs. Financing of up to EUR 30 Million through a Bond Loan with IPF Partners". Lyon. |
2019-11-05 |
| Polyplus-transfection S.A.. (7/6/18). "Press Release: Polyplus-transfection Launches New Advanced System for Transient Protein Expression in CHO cells". Strasbourg. |
2018-07-06 |
| Polyplus-transfection S.A.. (4/29/20). "Press Release: Growth Investment Is Set to accelerate Polyplus’ Expansion in Partnership with Warburg Pincus and ArchiMed". Illkirch. |
2020-04-29 |
| Polyplus-transfection S.A.. (3/9/22). "Press Release: Polyplus-transfection Acquires Biowire to further Expand into Asia-Pacific Gene and Cell Therapy Markets". Strasbourg. |
2022-03-09 |
| Polyplus-transfection S.A.. (12/17/22). "Press Release: Polyplus Acquires Xpress Biologics to Expand Plasmid DNA Offer". Strasbourg. |
2022-12-17 |
| Polyplus-transfection S.A.. (12/13/18). "Press Release: Polyplus-transfection further Expands Transfection Reagent Portfolio for Cell and Gene Therapy GMP production". Strasbourg. |
2018-12-13 |
| Polyplus-transfection S.A.. (11/29/18). "Press Release: Polyplus-transfection Launches a Powerful Nanotechnology for DNA Transfection Composed of jetOptimus Reagent". |
2018-11-29 |
| Polyplus-transfection S.A.. (11/2/20). "Press Release: Polyplus-transfection Names Mario Philips as Chief Executive Officer". Illkirch. |
2020-11-02 |
| Pixium Vision S.A.. (6/25/21). "Press Release: Pixium Vision Appoints Experienced International Financial Executive Offer Nonhoff as CFO". Paris. |
2021-06-25 |
| Pierre Fabre. (3/1/24). "Press Release: Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, Exarafenib, to Pierre Fabre Laboratories". San Francisco, CA & Castres. |
2024-03-01 |
| Pierre Fabre. (1/26/24). "Press Release: Eau Thermale Avène Hits a Billion Euros in Turnover, and Strengthens Its Medical Positioning". Toulouse. |
2024-01-26 |
| Pierre Fabre S.A.. (5/4/18). "Press Release: Pierre Fabre Group – Appointment of a New Chief Executive Officer". Castres. |
2018-05-04 |
| Pierre Fabre S.A.. (5/18/18). "Press Release: Pierre Fabre and Roche Extend Collaboration Agreement on Companion Diagnostic Development". Castres. |
2018-05-18 |
| Pierre Fabre S.A.. (5/14/18). "Press Release: Pierre Fabre Pharmaceuticals and the Start-up BioSerenity Join Forces to Develop the First Connected Fabric for the Detection and Medical Monitoring of Urinary Disorders". Castres. |
2018-05-14 |
| Pierre Fabre S.A.. (3/3/17). "Press Release: Pierre Fabre and Hill Dermaceuticals, Inc. Announce a Strategic Commercial Partnership for Tolak (fluorouracil) Cream 4% in the USA and Beyond". Lavaur & Sanford, FL. |
2017-03-03 |
| Pierre Fabre S.A.. (3/21/19). "Press Release: Institut Curie and Pierre Fabre Strengthen Their Immuno-oncology Partnership". Paris & Castres. |
2019-03-21 |
| Pierre Fabre S.A.. (10/7/21). "Press Release: Talem Therapeutics Announces Multi-Target Antibody Discovery Research Collaboration with Pierre Fabre". Victoria, BC & Castres. |
2021-10-07 |
| Pierre Fabre Laboratories. (1/10/24). "Press Release: Hervé Hoppenot, Incyte CEO, Is Appointed on the Board of Pierre Fabre Laboratories". Castres. |
2024-01-10 |
| Pherecydes Pharma S.A.. (1/29/21). "Press Release: Pherecydes Pharma Brings Forward the Closing of Its IPO to February 1, 2021, Given Its Strong Success With Investors [Not for US, CA, AU or JP]". Nantes. |
2021-01-29 |
| Pherecydes Pharma S.A.. (1/16/18). "Press Release: Pherecydes Pharma Raises €8.7m ($10.3m). Series B Financing Led by GO CAPITAL and Two Historical Investors, ACE Management and Auriga Partners". Romainville. |
2018-01-16 |
| Pharnext S.A.. (6/7/21). "Press Release: Pharnext Announces a New Financing Through a Convertible Bond Program for a Total Amount up to €81 Million Gross". Paris. |
2021-06-07 |
| Pharnext S.A.. (3/9/17). "Press Release: Pharnext Announces R&D Agreement with Galapagos to Generate a New Pipeline of Synergistic Drug Combinations". Paris. |
2017-03-09 |
| Pharnext S.A.. (2/7/17). "Press Release: Pharnext to Present at 2017 BIO CEO & Investor Conference". Paris. |
2017-02-07 |
| Pharnext S.A.. (10/19/17). "Press Release: First-Half 2017". Paris. |
2017-10-19 |
| Pharnext S.A.. (1/4/17). "Press Release: Pharnext to Attend January Investor Conferences". Paris. |
2017-01-04 |
| Pharnext S.A.. (1/3/17). "Press Release: Pharnext Announces the Amendment to the Liquidity Contract with French Broker Gilbert Dupont and the Annual Update on Its Liquidity Agreement". Paris. |
2017-01-03 |
| Pharnext S.A.. (1/23/19). "Press Release: Pharnext Raises €15 Million without Discount". Paris. |
2019-01-23 |
| PathoQuest SAS. (9/25/18). "Press Release: PathoQuest Names Dr. Christiane Honisch to Board of Directors". Paris. |
2018-09-25 |
| PathoQuest SAS. (7/10/18). "Press Release: PathoQuest Announces New Appointments to Executive Leadership Team". |
2018-07-10 |
| PathoQuest SAS. (11/9/21). "Press Release: PathoQuest Closes up to €15 Million Series B Financing Round Led by Growth Investor SHS Capital". Paris & Tübingen. |
2021-11-09 |
| PathoQuest SAS. (10/31/18). "Press Release: PathoQuest Achieves Illumina Propel Certification". |
2018-10-31 |
| PathoQuest SAS. (09/5/19). "Press Release: PathoQuest Secures 8 Million Euros in New Financing". Paris. |
2019-09-05 |
| PathoQuest SAS. (09/29/20). "Press Release: PathoQuest Obtains Pharmaceutical Establishment Status from French ANSM for Its Biological Drug Testing Activities". Paris. |
2020-09-29 |
| PAI Partners SAS. (5/11/17). "Press Release: PAI Partners Enters into Exclusive Negotiations for the Acquisition of ELITech". Paris. |
2017-05-11 |
| PAI Partners SAS. (12/27/23). "Press Release: PAI Partners Enters into Agreement for the Sale of ELITech Group to Bruker Corporation". |
2023-12-27 |
| Owkin. (9/13/22). "Press Release: Owkin and 12 Partners Launch $14 Million NIH Project to Allow Doctors to Spot Cancer, Depression and other Diseases from the Human Voice". |
2022-09-13 |
| Owkin. (3/21/24). "Press Release: Owkin Expands Collaboration with Sanofi Leveraging AI for Drug Positioning in immunology". |
2024-03-21 |
| Owkin. (12/2/19). "Press Release: Owkin Teams up with NVIDIA and King's College London to Deliver AI to Hospitals While Protecting Patient Data With Federated Learning". Paris & New York. |
2019-12-02 |
| Owkin. (12/19/23). "Press Release: Owkin Enters Collaboration Agreement with MSD to Develop AI-powered Diagnostics for Cancer". |
2023-12-19 |
| Owkin. (11/21/23). "Press Release: Owkin Expands Reach of AI Diagnostic for Colorectal Cancer through Integration with Sectra". |
2023-11-21 |
| Owkin. (10/4/22). "Press Release: Owkin Appoints Sanofi’s Global Head of Partnering Alban de La Sablière as Chief Business Officer". |
2022-10-04 |
| Owkin. (10/17/23). "Press Release: Servier Partners with Owkin with the Aim of Discovering and Developing AI-driven Precision Therapeutics". |
2023-10-17 |
| Owkin. (1/16/18). "Press Release: Owkin Closes $11 Million Series A Financing Round". New York, NY. |
2018-01-16 |
| Osivax SAS. (7/8/20). "Press Release: Osivax Receives Over EUR 30m in Public Funding to Support Development of Universal Coronavirus & Influenza Vaccines". Lyon. |
2020-07-08 |
| OSE Immunotherapeutics S.A.. (9/7/17). "Press Release: OSE Immunotherapeutics Reports on First-Half 2017 Financial Results and Provides Update on Clinical Advances of its Product Portfolio". Nantes. |
2017-09-07 |
| OSE Immunotherapeutics S.A.. (7/19/17). "Press Release: OSE Immunotherapeutics Receives €9.2 Million Grant from Bpifrance “Invest in the Future Program” for Development of New Immune Checkpoint Inhibitor OSE-172 (Effi-DEM)". Nantes. |
2017-07-19 |
| OSE Immunotherapeutics S.A.. (2/7/19). "Press Release: OSE Immunotherapeutics and Servier Announce First Option within Global License Agreement Exercised for further Clinical Development and Potential Commercialisation of OSE-127 in Autoimmune Diseases". |
2019-02-07 |
| OSE Immunotherapeutics S.A.. (2/7/17). "Press Release: OSE Immunotherapeutics to Present Corporate Overview at Upcoming BIO CEO & Investor Conference New York February 13-14, 2017". Nantes. |
2017-02-07 |
| OSE Immunotherapeutics S.A.. (2/12/20). "Press Release: OSE Immunotherapeutics Announces Artificial Intelligence Antibody Drug Development Collaboration with MAbSilico". Nantes. |
2020-02-12 |
| OSE Immunotherapeutics S.A.. (10/7/22). "Press Release: OSE Immunotherapeutics Appoints Nicolas Poirier as Chief Executive Officer". Nantes. |
2022-10-07 |
| Orakl Oncology SAS. (10/4/23). "Press Release: Orakl Oncology Raises €3 Million to Develop Its Techbio Platform for Precision Oncology". Paris. |
2023-10-04 |
| Onxeo S.A.. (7/27/18). "Press Release: Onxeo Reports Half-Year 2018 Financial Results and Provides Business Outlook". Paris. |
2018-07-27 |
| Onxeo S.A.. (4/24/18). "Press Release: Onxeo Announces Initiation of DRIIV Phase I Clinical Trial of AsiDNA for Treatment of Advanced Solid Tumor". Paris. |
2018-04-24 |
| Onxeo S.A.. (4/13/18). "Press Release: Onxeo Implements an Equity Line Financing Including an Incentive Program with Nice & Green SA. Cash for Operations Extended to Q3 2020". Montpellier. |
2018-04-13 |
| Onxeo S.A.. (10/17/17). "Press Release: Onxeo Reports First Instance Decision from the Commercial Court of Paris in the Lawsuit against SpeBio/SpePharm". Paris. |
2017-10-17 |
| Onxeo S.A.. (1/3/22). "Press Release: Onxeo Appoints Julien Miara as New Interim CEO". Paris. |
2022-01-03 |
| Oncovita SAS. (7/2/19). "Press Release: Oncovita Signs Exclusive Licensing Agreement with Institut Pasteur. Agreement Will Cover Development and Marketing of Oncolytic Virotherapies". Paris. |
2019-07-02 |
| Oncodesign S.A.. (2/24/22). "Press Release: Abzena, Alira Health and Oncodesign Launch DRIVE-Biologics to Support Access to Specialist Services from Discovery to Clinical Development for Oncology and Inflammation". Cambridge, Framingham, MA & Dijon. |
2022-02-24 |
![[LSE] Life-Sciences-Europe.com - The European Life Sciences Web Portal](/images/basics/lse-life-sciences-europe-portal-logo.svg){kind=logo}
1 2 3 4 5 6 7 8 9 10 11 
Source
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20230710-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 120x600px](/banner/iito-20181119-120-600-lsus-life-sciences-usa-com.jpg)
